Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide with Transarterial Hepatic Embolization in Unresectable Hepatocellular Carcinoma
NCT03107416Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bumetanide in hepatocellular carcinoma (HCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Local Tumor Progression Rate at 1 year. Started Apr 2017; status: active, not recruiting.
02
Drugs
bumetanide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03107416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107416.